MDS/MPN With Ring Sideroblasts and Thrombocytosis

Master implementation of the techniques of flow cytometry in diagnosing complex haematological diseases and malignancies in patients, worldwide. Featuring World Health Organization recommendations on pre-analytical steps, instrument settings and panel construction, this invaluable manual offers invaluable support for those researching, practising and analyzing the cause of hematological malignancies. Authored by leading experts, this book puts flow-cytometry into everyday context. With a focus on multicolour panels, the manual provides readers an experienced understanding of effective, implementation techniques. Practitioners of all levels are offered a background in a variety of diseases presented alongside the most current methodology. Wide-ranging and comprehensive; detailed images of healthy blood, bone marrow and lymph-nodes are illustrated throughout, allowing for effective diagnosis. Through engaging with differential diagnoses, the manual offers an understanding of similar symptoms and mimicking malignancies, avoiding inaccurate results. Featuring in-depth descriptions of chronic diseases; users can reach accurate diagnosis, first time.

Hematology Board Review: Blueprint Study Guide and Q&A is a concise, outline-based study guide covering all topics that appear on the Hematology Certification Exam. The book includes all topics listed in the American Board of Internal Medicine (ABIM) blueprint as essential material for the exam and highlights topic areas that are often found on the test. For hematology and oncology fellows as well as practicing clinicians needing a refresher before taking MOC, this handy study guide provides succinct overviews of all blood disorders, syndromes and diseases with practice questions on the go. Each disorder or disease-based chapter provides the same structure for ease of use beginning with the epidemiology, and followed by the etiology and risk factors, signs and symptoms, diagnostic criteria, indications for treatment, prognostic factors, treatment recommendations, and special considerations. The authors provide the most accurate and up-to-date information, including well-established treatment regimens for a variety of blood disorders, including iron disorders, bone marrow failure syndromes, platelet and megakaryocytic disorders, hemostasis, thrombosis, and hematologic malignancies. Later chapters review other major subspecialty areas found on the exam including transfusion medicine and hematopoietic cell transplantation. With 200 board-style questions and answers with detailed rationales, Hematology Board Review is the go-to, quick review for any trainee preparing for initial certification and for hematologists or oncologists preparing for recertification. Key Features: Includes 200 board-style questions and answers with rationales Provides key point summaries of each topic area for quick study and easy recall Thorough coverage of hematologic malignancies, blood disorders, transfusion medicine, hematopoietic cell transplantation, and standard treatment regimens Tables providing key data and information related to staging, treatment options, and disease classifications

Hematologic malignancies (HMs) represent a group of hematologic cancers originating from bone marrow or lymphoid organs. Currently, leukaemia, lymphoma, and multiple myeloma are the most common HMs. Conventional treatments for HMs include bone marrow transplantation, radiotherapy, chemotherapy, and immunotherapy. Despite the significant achievements obtained over the past decade in the drug therapy of HMs, tumor metastasis and relapse in patients often occurred after an initial response, indicating the generation of drug resistance to current therapies. Moreover, many clinically used therapeutic drugs are often associated with dose-related side effects and a lack of specificity to tumor tissues. The tumor microenvironment (TME) in HMs consists of a complicated network of cellular interactions and signaling cross-talking within the bone marrow cavity, and it plays an essential role in the progression and metastasis of HM. Furthermore, the TME in HMs has formed physiologic barriers such as immunosuppressive microenvironment, upregulated anti-apoptotic system, drug resistance, etc. to facilitate drug resistance and relapse of HMs. It has become widely accepted that effective treatment against HMs may require targeting both the cancer cell and TME.